Chicago、ILにおける転移性癌の臨床試験
Chicagoとその周辺地域（約30マイル以内）の拠点で、転移性癌に関する45件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
被験者募集中第3相
- City of Hope, Chicago
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- Mount Sinai Hospital Medical Center, Chicago
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- 他3件
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
被験者募集中第1相
- Northwestern University, Chicago
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
被験者募集中第1相
- University of Chicago Hospital, Chicago
PRE-ISPY Phase I/II Oncology Platform Program
被験者募集中第1/2相
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
被験者募集中第3相
- Illinois Cancer Specialists, Chicago
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
被験者募集中第3相
- Research Site, Chicago
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
被験者募集中第3相
- University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center), Chicago
- University of Illinois Hospital and Health Sciences System, Chicago
- Illinois Cancer Specialists, Chicago
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
被験者募集中第1/2相
- University of Chicago, Chicago
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
被験者募集中第3相
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- The University of Chicago Medicine, Chicago
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
被験者募集中第3相
- University of Illinois at Chicago, Chicago
- University of Chicago Medical Center, Chicago
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
被験者募集中第3相
- City of Hope, Chicago, Chicago
- Northwestern Memorial Hospital, Chicago
- University of Illinois at Chicago, Chicago
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
被験者募集中第1/2相
- The University of Chicago Medical Center - Duchossois Center for Advanced Medicine, Chicago
CREO - Microwave Ablation Feasibility Study
被験者募集中
- Rush University Medical Center, Chicago
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
被験者募集中第1相
- Northwestern University ( Site 0101), Chicago
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- University of Illinois at Chicago, Chicago
- University of Chicago Hospital, Chicago
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
被験者募集中第2相
- Northwestern University, Chicago
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
被験者募集中第3相
- Northwestern University, Chicago
BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
被験者募集中第1/2相
- Northwestern University, Chicago
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
被験者募集中第1相
- The University of Chicago Medical Center (UCMC), Chicago
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
被験者募集中第2相
- Research Site, Chicago
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
被験者募集中第1相
- University of Chicago Comprehensive Cancer Center, Chicago
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
被験者募集中第3相
- Research Site, Chicago
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- The University of Chicago Medicine, Chicago
A Study of PYX-201 in Advanced Solid Tumors
被験者募集中第1相
- University of Chicago Medicine, Chicago
A Study of LY4175408 in Participants With Advanced Cancer
被験者募集中第1相
- The University of Chicago Medical Center (UCMC), Chicago
REMASTer: REcurrent Brain Metastases After SRS Trial
被験者募集中
- University of Chicago, Chicago
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
被験者募集中第3相
- Northwestern University, Chicago
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
被験者募集中第2相
- Northwestern University, Chicago
CT-95 in Advanced Cancers Associated With Mesothelin Expression
被験者募集中第1相
- Context Investigational Site, Chicago
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
被験者募集中第1/2相
- University of Chicago Medical Center, Chicago
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
被験者募集中第1/2相
- University of Chicago, Chicago
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
被験者募集中第3相
- University of Illinois Cancer Center, Chicago
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
被験者募集中第2/3相
- Northwestern Memorial Hospital, Chicago
- University of Chicago Medical Center, Chicago
Venetoclax Basket Trial for High Risk Hematologic Malignancies
被験者募集中第1相
- Ann & Robert H Lurie Children's Hospital of Chicago, Chicago
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
被験者募集中観察研究
- John H Stroger Jr Hospital of Cook County, Chicago
STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study
被験者募集中第1相
- University of Illinois at Chicago, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
被験者募集中第1相
- The University of Chicago Comprehensive Cancer Center, Chicago
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
被験者募集中第3相
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
被験者募集中第1相
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Chicago
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
被験者募集中第1相
- University Of Chicago Medicine Comprehensive Cancer Center, Chicago
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
被験者募集中第1相
- Northwestern University, Chicago
- University of Illinois, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
被験者募集中第1相
- University of Chicago, Chicago
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
被験者募集中第1/2相
- Northwestern University, Chicago
他の都市における転移性癌の試験
- Houston, TX104件の研究
- New York City, NY93件の研究
- Nashville, TN70件の研究
- Boston, MA63件の研究
- Los Angeles, CA57件の研究
- St. Louis, MO54件の研究
- Arlington, VA53件の研究
- Philadelphia, PA46件の研究
- San Antonio, TX44件の研究
- Washington, DC43件の研究
- Dallas, TX42件の研究
- Seattle, WA39件の研究
Chicagoにおける他の研究
- 非小細胞肺癌61件の研究
- 乳がん59件の研究
- がん（全種類）51件の研究
- 前立腺がん45件の研究
- 肺がん41件の研究
- 肥満症41件の研究
- 卵巣がん36件の研究
- 大腸癌34件の研究
- 脳卒中34件の研究
- 心不全31件の研究
- 過体重29件の研究
- 頭頸部扁平上皮癌26件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。